此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

Odevixibat 在 Alagille 综合征患者中的长期安全性和有效性 (ASSERT-EXT)

2026年10月20日 更新者:Albireo, an Ipsen Company

一项评估 Odevixibat (A4250) 在 Alagille 综合征 (ASSERT-EXT) 患者中的长期安全性和有效性的开放标签研究

The purpose of this study is to assess the long-term safety and effectiveness of odevixibat in participants with Alagille syndrome (ALGS).

The participants of this study will have ALGS a rare genetic disorder that can affect multiple organ systems of the body including the liver, heart, skeleton, eyes and kidneys. Common symptoms, which often develop during the first three months of life, include blockage of the flow of bile from the liver (cholestasis), yellowing of the skin and mucous membranes (jaundice), poor weight gain and growth and severe itching (pruritis).

The drug used for the study is odevixibat and was authorized for the treatment of cholestatic pruritus in infants with ALGS over 12 months of age by the United States Food and Drug Administration on 13 June 2023.

研究概览

地位

主动,不招人

干预/治疗

详细说明

This Phase 3, open-label, multi-center extension study will have two groups of participants: Cohort 1 (participants who participated in Study A4250-012 [NCT04674761; ASSERT] and meet the entry criteria for this study) and Cohort 2 (infants under 12 months of age) with ALGS.

The study will consist of 2 or 3 periods:

  1. A 'Treatment period' of 72 weeks (cohort 1) or 12 weeks (cohort 2). Participants will visit the clinic every 4 to 12 weeks and will receive a dose of 120 μg/kg odevixibat daily.
  2. An 'Optional extension period' where participants who wish to continue receiving odevixibat after the 'treatment period' will have the opportunity to remain on treatment with visits every 16 weeks until the drug is commercially available. The optional extension is available provided continued use is supported by the risk-benefit profile, the participant has not been previously withdrawn or discontinued from the study, and the study is not terminated by the Sponsor.
  3. A 'Safety follow-up period' of 4 weeks (cohort 1) or 2 weeks (cohort 2). The Safety Follow-up Period will not occur for those who remain on treatment in the optional extension period.

Participants will need to complete an e-diary and questionnaires throughout the study (cohort 1 only). Participants will undergo blood samplings, urine collections (cohort 1 only), physical examinations, and clinical evaluations. They may continue some other medications, but the details need to be recorded.

研究类型

介入性

注册 (实际的)

62

阶段

  • 第三阶段

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

      • Istanbul、土耳其(türkiye)
        • Istanbul University Istanbul Medical Faculty Hospital
      • Berlin、德国、13353
        • Charité - Universitätsmedizin Berlin
      • Hanover、德国、30625
        • Medizinische Hochschul
      • Tübingen、德国、72076
        • Universitatsklinik fur Kinder-und Jugendmedizin Tubingen
      • Florence、意大利
        • AOU Meyer
      • Padova、意大利、35128
        • Azienda Ospedale University
      • Rome、意大利、00165
        • Ospedale Pediatrico Bambino Gesu
      • Brussels、比利时、1200
        • Cliniques Universitaires Saint-Luc Bruxelles
      • Bron、法国、69677
        • Hôpital Femme Mère Enfant de Lyon
      • Lille、法国
        • Antenne pediatrique du CIC-Hopital Jeanne De Flandre
      • Paris、法国、75015
        • Hopital Necker Enfants Malades
      • Warsaw、波兰、04-730
        • Instytut Pomnik-Centrum Zdrowia Dzieck
    • California
      • San Diego、California、美国、92123
        • Rady Children's Hospital
      • San Francisco、California、美国、94158
        • UCSF
    • Georgia
      • Atlanta、Georgia、美国、30329
        • Children's Healthcare of Atlanta
    • Indiana
      • Indianapolis、Indiana、美国、46202
        • Riley Hospital for Children at IU Health
    • Maryland
      • Baltimore、Maryland、美国、21287
        • Johns Hopkins Hospital
    • Massachusetts
      • Boston、Massachusetts、美国、02115
        • Boston Children's Hospital
    • Missouri
      • Kansas City、Missouri、美国、64018
        • Children's Mercy Hospital and Clinics
    • New York
      • New Hyde Park、New York、美国、11042
        • Northwell Health System
      • New York、New York、美国、10016
        • Hassenfeld Children's Hospital at NYU Langone
      • New York、New York、美国、10032
        • New York-Presbyterian / Columbia University Irving Medical Center
      • The Bronx、New York、美国、10467
        • The Childrens Hospital at Montefiore Albert Einstein School of Medicine
    • North Carolina
      • Durham、North Carolina、美国、27710
        • Atrium Health Carolinas Medical
    • Ohio
      • Cincinnati、Ohio、美国、45229
        • Cincinnati Children's Hospital
    • Oregon
      • Portland、Oregon、美国、97239
        • Oregon Health Science University School of Medicine
    • Tennessee
      • Nashville、Tennessee、美国、37232
        • Monroe Carell Jr. Childrens Hospital at Vanderbilt
    • Texas
      • Dallas、Texas、美国、75207
        • Childrens Medical Center of Dallas University of Texas Southwestern
      • Houston、Texas、美国、77030
        • Texas Children's Hospital
      • San Antonio、Texas、美国、78215
        • Texas Liver Institute
      • Birmingham、英国
        • Birmingham Women's and Children's NHS Foundation Trust
      • London、英国、SE5 9RS
        • King's College Hospital NHS Foundation Trust King's College Hospital Paediatric Research
      • Groningen、荷兰、9713 GZ
        • Universitair Medisch Centrum Groningen
      • Utrecht、荷兰
        • Wilhelmina Children's Hospital UMCU Utrecht
      • Kuala Lumpur、马来西亚、59100
        • University of Malaya Medical Center

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

  • 孩子
  • 成人
  • 年长者

接受健康志愿者

不

有资格学习的性别

全部

描述

Inclusion Criteria:

Cohort 1 :

  1. Completion of the 24-week Treatment Period of Study A4250-012
  2. Signed informed consent and assent as appropriate. Patients who turn 18 years of age (or legal age per country) during the study will be required to re-consent to remain on the study
  3. Caregivers (and age-appropriate patients) must be willing and able to use an electronic diary (eDiary) device as required by the study
  4. Sexually active males and females must agree to use a reliable contraceptive method with ≤1% failure rate (such as hormonal contraception, intra-uterine device, or complete abstinence) from signed informed consent through 90 days after last dose of study drug.

Cohort 2 :

  1. Infant with clinically confirmed ALGS , ≤11 months of age at Study Day 1
  2. Body weight ≥2 kg at Study Day 1
  3. Gestational age ≥36 weeks. For children born with gestational age between 32 and 36 weeks, a postmenstrual age of ≥36 weeks is required .
  4. Signed parent/legal guardian informed consent.

Exclusion Criteria:

Cohort 1 :

  1. Decompensated liver disease, history or presence of clinically significant ascites, variceal hemorrhage, and/or encephalopathy
  2. Patients who were not compliant with study drug treatment or procedures in Study A4250-012
  3. Any other conditions or abnormalities which, in the opinion of the investigator, may compromise the safety of the patient, or interfere with the patient participating in or completing the study
  4. Known hypersensitivity to any components of odevixibat

Cohort 2 :

  1. Patient with past medical history or ongoing presence of other types of liver disease including, but not limited to, the following:

    1. Biliary atresia of any kind
    2. Progressive familial intrahepatic cholestasis (PFIC)
    3. Benign recurrent intrahepatic cholestasis
  2. Patient with a past medical history or ongoing presence of any other disease or condition known to interfere with the absorption, distribution, metabolism (specifically bile acid metabolism), or excretion of drugs in the intestine, including but not limited to, inflammatory bowel disease

  3. Patient with past medical history or ongoing chronic diarrhea requiring intravenous fluid or nutritional intervention for treatment of the diarrhea and/or its sequelae

  4. Patient has a confirmed past diagnosis of infection with human immunodeficiency virus or other present and active, clinically significant chronic infection

  5. Recent infection requiring hospitalization or treatment with parenteral anti-infective within 4 weeks of Study Day 1 or completion of oral anti-infective treatment within 2 weeks prior to the Screening Visit

  6. Cancer diagnosis (except for basal cell carcinoma)

  7. Chronic kidney disease with an impaired renal function and a glomerular filtration rate <70 mL/min/1.73 m2

  8. Patient with surgical history of disruption of the enterohepatic circulation (biliary diversion surgery) within 6 months prior to the Screening Visit

  9. Patient has had a liver transplant, or a liver transplant is planned within 6 months of Study Day 1

  10. Decompensated liver disease, history or presence of clinically significant ascites, variceal hemorrhage, and/or encephalopathy

  11. International normalized ratio (INR) >1.4 (the patient may be treated with Vitamin K, and if INR is ≤1.4 at resampling the patient may be enrolled)

  12. Serum alanine aminotransferase (ALT) >10 × upper limit of normal (ULN) at Screening

  13. Serum ALT >15 × ULN at any time point during the last 6 months unless an alternate etiology was confirmed for the elevation

  14. Total bilirubin >15 × ULN at Screening

  15. Patient suffers from uncontrolled, recalcitrant pruritic condition other than ALGS. Examples include, but not limited to, refractory atopic dermatitis or other primary pruritic skin diseases.

  16. Patient exposed to alcohol or substance abuse in utero

  17. Bile acid or lipid binding resins and medications that slow gastrointestinal motility

  18. Patient has had investigational exposure to a drug, biologic agent, or medical device within 30 days prior to the Screening Visit, or 5 half-lives of the study agent, whichever is longer

  19. Any other conditions or abnormalities which, in the opinion of the investigator may compromise the safety of the patient, or interfere with the patient participating in or completing the study

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:不适用
  • 介入模型:单组作业
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
实验性的:Odevixibat (A4250)

Capsules for oral administration once daily for 72 weeks.

Odevixibat is a small molecule and selective inhibitor of IBAT.

其他名称:
  • A4250

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
伴随药物相对于基线的变化。
大体时间:基线至第 12 周(第 2 组)。
基线至第 12 周(第 2 组)。
脂溶性维生素水平较基线的变化。
大体时间:基线至第 12 周(第 2 组)。
基线至第 12 周(第 2 组)。
Change from baseline in pruritus
大体时间:Baseline to week 72 (cohort 1).

Assessed as change in scratching score as measured by measured by the Albireo Observer-Reported Outcome Caregiver Instrument.

Baseline to week 72 (cohort 1).
Percentage of participants with Treatment Emergent Adverse Event (TEAEs) and Serious Adverse Events (SAEs)
大体时间:Baseline to week 12 (cohort 2).

An Adverse event (AE) is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. A serious adverse event (SAE) is an AE that results in any of following outcomes: death; life threatening; persistent/significant disability/incapacity; initial or prolonged inpatient hospitalization; congenital anomaly/birth defect or was otherwise considered medically important. Treatment-emergent adverse events. TEAEs included both Serious TEAEs and non-serious TEAEs.

Baseline to week 12 (cohort 2).
Percentage of participants with clinically significant changes from baseline in Physical Examination
大体时间:Baseline to week 12 (cohort 2).

The clinical significance will be graded by the investigator.

Baseline to week 12 (cohort 2).
Percentage of participants with clinically significant changes in Laboratory Parameters
大体时间:Baseline to week 12 (cohort 2).

The following laboratory parameters will be reported: blood chemistry, hematology and coagulation. The clinical significance will be graded by the investigator.

Baseline to week 12 (cohort 2).
Percentage of participants with clinically significant changes from baseline in Vital Signs.
大体时间:Baseline to week 12 (cohort 2).

The clinical significance will be graded by the investigator.

Baseline to week 12 (cohort 2).

次要结果测量

结果测量
措施说明
大体时间
血清胆汁酸水平相对于基线的变化
大体时间:基线至第 72 周(第 1 组)。
基线至第 72 周(第 1 组)。
血清胆汁酸水平相对于基线的变化。
大体时间:基线至第 72 周(第 1 组)。
基线至第 72 周(第 1 组)。
体检较基线发生变化的参与者人数
大体时间:基线至第 72 周(第 1 组)。
基线至第 72 周(第 1 组)。
生命体征较基线发生变化的参与者人数
大体时间:基线至第 72 周(第 1 组)。
基线至第 72 周(第 1 组)。
伴随药物相对于基线的变化
大体时间:基线至第 72 周(第 1 组)。
基线至第 72 周(第 1 组)。
实验室测试结果相对于基线的变化 药代动力学 (PK) Cmax [时间范围:第 1 天、第 4 周、第 8 周和第 12 周]
大体时间:基线至第 72 周(第 1 组)。
基线至第 72 周(第 1 组)。
研究药物血浆浓度相对基线的变化
大体时间:第 1 天、第 4 周、第 8 周和第 12 周(第 1 组)。
第 1 天、第 4 周、第 8 周和第 12 周(第 1 组)。
药效参数:血清胆汁酸水平的变化
大体时间:基线至第 12 周(第 2 组)。
基线至第 12 周(第 2 组)。
Change from baseline in patient reported and observer reported itching and scratching severity scores
大体时间:Baseline to week 72 (cohort 1).

Assessed by the the Albireo ObsRO/ Patient Reported Outcomes (PRO) instruments. The Albireo ObsRO/PRO scratching and itch severity items use 0 to 4 response scales, where each response is distinguished by a unique facial expression, verbal anchor, number, and color code.

Baseline to week 72 (cohort 1).
Percentage of participants achieving a clinically meaningful decrease in pruritus (pruritus responders)
大体时间:Baseline to week 72 (cohort 1).

Assessed by the Albireo ObsRO/patient reported outcomes (PRO) instruments

Baseline to week 72 (cohort 1).
Change from baseline in sleep parameters.
大体时间:Baseline to week 72 (cohort 1).

Assessed with the Albireo ObsRO/PRO instruments (e.g: tiredness and number of awakenings).

Baseline to week 72 (cohort 1).
Change from baseline in Pediatric Quality of Life Inventory (PedsQL) scores.
大体时间:Baseline to week 72 (cohort 1).

The PedsQL instrument consists of 36 questions and uses a 5-point response scales, where higher scores indicates worst symptoms.

Baseline to week 72 (cohort 1).
Change from baseline in in Global Symptom Relief: Patient Global Impression of Improvement (PGIC) score.
大体时间:Baseline to Weeks 4, 12, 24, 48 and 72 (cohort 1).

The Patient Global Impression of Change (PGIC) is a patient-reported instrument that measures change in overall status on a scale ranging from one ("very much improved") to seven ("very much worse").

Baseline to Weeks 4, 12, 24, 48 and 72 (cohort 1).
Change from baseline in in Global Symptom Relief: Clinical Global Impression of Improvement (CGIC) score.
大体时间:Baseline to Weeks 4, 12, 24, 48 and 72 (cohort 1).

The Clinical Global Impression of Change (CGIC) is a clinician-reported instrument that measures change in overall status on a scale ranging from one ("very much improved") to seven ("very much worse").

Baseline to Weeks 4, 12, 24, 48 and 72 (cohort 1).
Change from baseline in in Global Symptom Relief: Caregiver Global Impression of Change (CaGIC) score
大体时间:Baseline to Weeks 4, 12, 24, 48 and 72 (cohort 1).

The caregiver Global Impression of Change is a caregiver-reported instrument that measures change in overall status on a scale ranging from one ("very much improved") to seven ("very much worse").

Baseline to Weeks 4, 12, 24, 48 and 72 (cohort 1).
Percentage of participants with Treatment Emergent Adverse Event (TEAEs) and Serious Adverse Events (SAEs)
大体时间:Baseline to week 72 (cohort 1).

An Adverse event (AE) is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. A serious adverse event (SAE) is an AE that resultes in any of following outcomes: death; life threatening; persistent/significant disability/incapacity; initial or prolonged inpatient hospitalization; congenital anomaly/birth defect or was otherwise considered medically important. Treatment-emergent adverse events. TEAEs included both Serious TEAEs and non-serious TEAEs.

Baseline to week 72 (cohort 1).

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 研究主任:Ipsen Medical Director、Ipsen

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2021年9月3日

初级完成 (估计的)

2027年2月15日

研究完成 (估计的)

2027年2月15日

研究注册日期

首次提交

2021年8月13日

首先提交符合 QC 标准的

2021年9月1日

首次发布 (实际的)

2021年9月5日

研究记录更新

最后更新发布 (实际的)

2026年10月23日

上次提交的符合 QC 标准的更新

2026年10月20日

最后验证

2026年10月1日

更多信息

与本研究相关的术语

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

是的

IPD 计划说明

Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, annotated case report form, statistical analysis plan, and dataset specifications.

Patient level data will be anonymized and study documents will be redacted to protect the privacy of study participants.

IPD 共享时间框架

Where applicable, data from eligible studies are available 6 months after the studied medicine and indication have been approved in the US and/or EU.

IPD 共享访问标准

Further details on Ipsen's sharing criteria and process for sharing are available here (https://www.ipsen.com/science/clinical-trials/clinical-data-transparency/).

药物和器械信息、研究文件

研究美国 FDA 监管的药品

是的

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅